Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1966 2
1969 1
1971 2
1972 1
1973 4
1974 5
1975 4
1976 2
1977 7
1978 5
1979 9
1980 7
1981 5
1982 2
1983 3
1984 3
1985 7
1986 6
1987 3
1988 5
1989 5
1990 2
1991 6
1992 6
1993 9
1994 12
1995 12
1996 8
1997 15
1998 17
1999 16
2000 25
2001 47
2002 38
2003 48
2004 48
2005 83
2006 93
2007 111
2008 129
2009 124
2010 137
2011 178
2012 173
2013 176
2014 149
2015 180
2016 211
2017 212
2018 221
2019 233
2020 263
2021 255
2022 255
2023 239
2024 98

Text availability

Article attribute

Article type

Publication date

Search Results

3,516 results

Results by year

Filters applied: . Clear all
Page 1
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial.
Subbiah V, Kreitman RJ, Wainberg ZA, Gazzah A, Lassen U, Stein A, Wen PY, Dietrich S, de Jonge MJA, Blay JY, Italiano A, Yonemori K, Cho DC, de Vos FYFL, Moreau P, Fernandez EE, Schellens JHM, Zielinski CC, Redhu S, Boran A, Passos VQ, Ilankumaran P, Bang YJ. Subbiah V, et al. Among authors: cho dc. Nat Med. 2023 May;29(5):1103-1112. doi: 10.1038/s41591-023-02321-8. Epub 2023 Apr 14. Nat Med. 2023. PMID: 37059834 Free PMC article. Clinical Trial.
Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial.
Wen PY, Stein A, van den Bent M, De Greve J, Wick A, de Vos FYFL, von Bubnoff N, van Linde ME, Lai A, Prager GW, Campone M, Fasolo A, Lopez-Martin JA, Kim TM, Mason WP, Hofheinz RD, Blay JY, Cho DC, Gazzah A, Pouessel D, Yachnin J, Boran A, Burgess P, Ilankumaran P, Gasal E, Subbiah V. Wen PY, et al. Among authors: cho dc. Lancet Oncol. 2022 Jan;23(1):53-64. doi: 10.1016/S1470-2045(21)00578-7. Epub 2021 Nov 24. Lancet Oncol. 2022. PMID: 34838156 Clinical Trial.
Unified Airway-Cystic Fibrosis.
Cho DY, Grayson JW, Woodworth BA. Cho DY, et al. Otolaryngol Clin North Am. 2023 Feb;56(1):125-136. doi: 10.1016/j.otc.2022.09.009. Epub 2022 Oct 18. Otolaryngol Clin North Am. 2023. PMID: 36266104 Review.
PEX13 prevents pexophagy by regulating ubiquitinated PEX5 and peroxisomal ROS.
Demers ND, Riccio V, Jo DS, Bhandari S, Law KB, Liao W, Kim C, McQuibban GA, Choe SK, Cho DH, Kim PK. Demers ND, et al. Among authors: cho dh. Autophagy. 2023 Jun;19(6):1781-1802. doi: 10.1080/15548627.2022.2160566. Epub 2023 Jan 1. Autophagy. 2023. PMID: 36541703 Free PMC article.
BiTE-Secreting CAR-γδT as a Dual Targeting Strategy for the Treatment of Solid Tumors.
Huang SW, Pan CM, Lin YC, Chen MC, Chen Y, Jan CI, Wu CC, Lin FY, Wang ST, Lin CY, Lin PY, Huang WH, Chiang YT, Tsai WC, Chiu YH, Lin TH, Chiu SC, Cho DY. Huang SW, et al. Among authors: cho dy. Adv Sci (Weinh). 2023 Jun;10(17):e2206856. doi: 10.1002/advs.202206856. Epub 2023 Apr 20. Adv Sci (Weinh). 2023. PMID: 37078788 Free PMC article.
3,516 results